XU Jiali 1 , HU Beibei 1 , MAO Qiuxia 1 , ZHANG Weiyun 1 , CHEN Junchun 2 , JIANG Junhong 1 , HUANG Jian'an 1 , QIAN Hongying 1 , ZENG Daxiong 1,3
  • 1. Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P. R. China;
  • 2. Department of Geriatric Medicine, Tongji Hospital Affiliated Tongji Medical College, Huazhong Universty of Science and Technology, Wuhan, Hubei 430030, P. R. China;
  • 3. Department of Pulmonary and Critical Care Medicine, Dushu Lake Hospital Affiliated to Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu 215006, P. R. China;
QIAN Hongying, Email: qianhy@suda.edu.cn; ZENG Daxiong, Email: zengdaxiong@suda.edu.cn
Coronavirus disease 2019; Venous thromboembolism; Padua score; Coagulation function; Anticoagulant
10.7507/1671-6205.202004121
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To evaluate the venous thromboembolism (VTE) risk and anticoagulant therapy in patients with coronavirus disease 2019 (COVID-19).Methods The patients with COVID-19 in Optics Valley Hospital of Wuhan Tongji Hospital from February 9, 2020 to March 29, 2020 were collected and analyzed. Padua scores were performed within 24 hours after admission. The relationship between Padua score, disease severity and 28 day prognosis was analyzed.Results COVID-19 was diagnosed in 102 cases. The age, fibrinogen and mortality of the severe group were significantly higher than those of the common group. The Padua score of the severe group was higher than that of the common group, but there was no statistical difference. The platelet count in the critical group was significantly lower than that in the severe group, while the prothrombin time (PT), activated partial thromboplastin time (APTT), and D dimer were significantly higher than that in the severe group, and the Padua score, anticoagulation ratio, and mortality were significantly higher than those in the severe group. According to Padua score 4, it was divided into VTE high risk group (≥ 4 points) and VTE low risk group (<4 points). The mortality, APTT, D dimer and fibrinogen of high risk group were significantly higher than those of low risk group. In the high-risk group of VTE, the anticoagulation rate was significantly higher than that in the low-risk group of VTE, but it was still only 41.7%. The mortality of patients with anticoagulation was lower than that of patients without anticoagulation.Conclusions Severe and critical novel coronavirus pneumonia patients have obvious coagulation dysfunction and high risk of VTE. Anticoagulant therapy may be associated with low mortality in patients with high risk of VTE, but the proportion of drug-induced anticoagulant intervention still needs to be improved.

Citation： XU Jiali, HU Beibei, MAO Qiuxia, ZHANG Weiyun, CHEN Junchun, JIANG Junhong, HUANG Jian'an, QIAN Hongying, ZENG Daxiong. VTE risk assessment and anticoagulant therapy in COVID-19 patients. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(2): 101-105. doi: 10.7507/1671-6205.202004121 Copy

  • Next Article

    Severe cavitary pneumonia caused by Legionella pneumophila serotype 6: a case report and literature review